A Novel Nogo‐A Receptor Antagonist Peptide Impedes Alzheimer's Disease Pathology by Nogo‐A/NgR/ROCK Signaling Pathway
Zheng Zhang, Huimin Tan, Fang Shi, Jiajia Dai, Weilong Ding, Junliang Li, Yuke Wang, Rui Yang, Xinke Xu, Cheng Chen, Fei Xiao, Li‐an Huang, Xiaoyan Liu, Rui Liao, Li Yan · 2026
Read A Novel Nogo‐A Receptor Antagonist Peptide Impedes Alzheimer's Disease Pathology by Nogo‐A/NgR/ROCK Signaling Pathway by Zheng Zhang, Huimin Tan, Fang Shi, Jiajia Dai, Weilong Ding, Junliang Li, Yuke Wang, Rui Yang, Xinke Xu, Cheng Chen, Fei Xiao, Li‐an Huang, Xiaoyan Liu, Rui Liao, Li Yan (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13473841.txt.
Description
Zhang and a large team in China tested in 2026 a fresh peptide, NAP2, as a brake on Alzheimer's disease in mice. The peptide blocks a dock called NgR1, which catches Nogo-A, a myelin protein that halts nerve growth. That catch fires a path named ROCK, tied to cell harm. The team gave the peptide for three months to mice bred to grow the disease's brain marks, then ran maze tests and brain checks.
Treated mice learned and recalled far better than their plain kin. Their brains held fewer amyloid plaques, the sticky clumps of the disease, and less of the worst clump form. Spines on brain cells, the buds that hold links, grew back in count. Tau, the twin mark protein, bore less of its harm linked tags. The peptide also saved cell power plants from clump harm, and its grip on the ROCK path was plain to see.
Catalog record
| CREATOR | Zheng Zhang, Huimin Tan, Fang Shi, Jiajia Dai, Weilong Ding, Junliang Li, Yuke Wang, Rui Yang, Xinke Xu, Cheng Chen, Fei Xiao, Li‐an Huang, Xiaoyan Liu, Rui Liao, Li Yan |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 48 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |